BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35395636)

  • 21. A multimodal imaging-based classification for pediatric diffuse intrinsic pontine gliomas.
    Pan C; Zhang M; Xiao X; Kong L; Wu Y; Zhao X; Sun T; Zhang P; Geng Y; Zuo P; Wang Y; Li X; Gu G; Li T; Wu Z; Zhang J; Zhang L
    Neurosurg Rev; 2023 Jun; 46(1):151. PubMed ID: 37358632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving long-term survival in diffuse intrinsic pontine glioma.
    Felker J; Broniscer A
    Expert Rev Neurother; 2020 Jul; 20(7):647-658. PubMed ID: 32543245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma.
    Yamasaki F; Nishibuchi I; Karakawa S; Kaichi Y; Kolakshyapati M; Takano M; Yonezawa U; Imano N; Taguchi A; Shimomura M; Taniguchi M; Onishi S; Okada S; Awai K; Sugiyama K; Nagata Y
    Pediatr Neurosurg; 2021; 56(1):1-9. PubMed ID: 33535215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry.
    Leach JL; Roebker J; Schafer A; Baugh J; Chaney B; Fuller C; Fouladi M; Lane A; Doughman R; Drissi R; DeWire-Schottmiller M; Ziegler DS; Minturn JE; Hansford JR; Wang SS; Monje-Deisseroth M; Fisher PG; Gottardo NG; Dholaria H; Packer R; Warren K; Leary SES; Goldman S; Bartels U; Hawkins C; Jones BV
    Neuro Oncol; 2020 Nov; 22(11):1647-1657. PubMed ID: 32506137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
    Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
    Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature.
    Dimentberg E; Marceau MP; Lachance A; Bergeron-Gravel S; Saikali S; Crevier L; Bourget C; Hawkins C; Jabado N; Giannakouros P; Renzi S; Larouche V
    J Pediatr Hematol Oncol; 2024 May; 46(4):211-215. PubMed ID: 38573000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric diffuse intrinsic pontine glioma: where do we stand?
    Rashed WM; Maher E; Adel M; Saber O; Zaghloul MS
    Cancer Metastasis Rev; 2019 Dec; 38(4):759-770. PubMed ID: 31802357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased natural killer cells in diffuse intrinsic pontine glioma patients.
    Zhang L; Yu H; Xue Y; Liu Y
    Childs Nerv Syst; 2020 Jul; 36(7):1345-1346. PubMed ID: 32418048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas.
    Klimo P; Nesvick CL; Broniscer A; Orr BA; Choudhri AF
    J Neurosurg Pediatr; 2016 Jan; 17(1):57-65. PubMed ID: 26474099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma.
    Jaimes C; Vajapeyam S; Brown D; Kao PC; Ma C; Greenspan L; Gupta N; Goumnerova L; Bandopahayay P; Dubois F; Greenwald NF; Zack T; Shapira O; Beroukhim R; Ligon KL; Chi S; Kieran MW; Wright KD; Poussaint TY
    AJNR Am J Neuroradiol; 2020 May; 41(5):874-881. PubMed ID: 32381545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
    Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ
    Front Oncol; 2019; 9():92. PubMed ID: 30873381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
    Lobon-Iglesias MJ; Giraud G; Castel D; Philippe C; Debily MA; Briandet C; Fouyssac F; de Carli E; Dufour C; Valteau-Couanet D; Sainte-Rose C; Blauwblomme T; Beccaria K; Zerah M; Puget S; Calmon R; Boddaert N; Bolle S; Varlet P; Grill J
    J Neurooncol; 2018 Mar; 137(1):111-118. PubMed ID: 29198053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
    Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
    Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.